Last reviewed · How we verify
Chloquinan (CHLORQUINALDOL)
Chloquinan (generic name: CHLORQUINALDOL) is a Standardized Chemical Allergen drug. It is currently in Phase 2 development.
Chloquinan works by inducing an allergic reaction on the skin, which helps to treat certain skin conditions.
Chloquinan (Chlorquinaldol) is a standardized chemical allergen classified as a small molecule. It is used to treat various skin conditions, although its exact target and approved indications are unknown. The commercial status of Chloquinan is unclear, and it may be patented or available as a generic medication. Key safety considerations include potential allergic reactions and interactions with other medications. Further research is needed to fully understand its pharmacological properties and clinical applications.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CHLORQUINALDOL |
|---|---|
| Drug class | Standardized Chemical Allergen |
| Target | Botulinum neurotoxin type A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Imagine your immune system is like a security guard that normally only reacts to real threats. Chloquinan tricks the security guard into thinking there's a threat, causing it to react and help clear up the skin condition. This reaction is what helps to treat the condition, but it can also cause some side effects.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chloquinan CI brief — competitive landscape report
- Chloquinan updates RSS · CI watch RSS
Frequently asked questions about Chloquinan
What is Chloquinan?
How does Chloquinan work?
What is the generic name of Chloquinan?
What drug class is Chloquinan in?
What development phase is Chloquinan in?
What does Chloquinan target?
Related
- Drug class: All Standardized Chemical Allergen drugs
- Target: All drugs targeting Botulinum neurotoxin type A
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing